MCID: TRN018
MIFTS: 58

Transitional Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Transitional Cell Carcinoma

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 72 49 14
Carcinoma, Transitional Cell 41 69
Transitional Cell Neoplasm 12 69
Transitional Cell Carcinoma of Bladder 69
Carcinoma Transitional Cell 51
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2671
MeSH 41 D002295
NCIt 46 C2930 C6783

Summaries for Transitional Cell Carcinoma

Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to renal pelvis transitional cell carcinoma and bladder papillary transitional cell neoplasm. An important gene associated with Transitional Cell Carcinoma is UPK2 (Uroplakin 2), and among its related pathways/superpathways are Development EGFR signaling pathway and Cytoskeletal Signaling. The drugs Vinblastine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, lymph node and prostate, and related phenotypes are growth/size/body region and digestive/alimentary

Wikipedia : 72 Transitional cell carcinoma (TCC) also urothelial carcinoma (UCC), is a type of cancer that typically... more...

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 336)
# Related Disease Score Top Affiliating Genes
1 renal pelvis transitional cell carcinoma 34.1 KRT7 UPK3A
2 bladder papillary transitional cell neoplasm 33.7 KRT20 TP53
3 invasive bladder transitional cell carcinoma 33.7 TP53 UPK3A
4 bladder urothelial carcinoma 32.2 CDH1 KRT20 KRT7 TP53 UPK3A
5 inverted papilloma 30.8 KRT20 KRT7 TP53
6 bladder squamous cell carcinoma 30.4 PTGS2 TP53 UPK2
7 papilloma 30.3 KRT20 KRT7 KRT8 TP53
8 paget disease, extramammary 30.3 ERBB2 KRT20 KRT7
9 clear cell adenocarcinoma 30.2 KRT20 KRT7 TP53
10 horseshoe kidney 30.1 EGFR ENO2 KRT20 KRT7
11 non-invasive bladder papillary urothelial neoplasm 30.1 TP53 UPK3A
12 bladder disease 30.1 UPK1A UPK2 UPK3A
13 papillary adenocarcinoma 30.1 CDH1 ERBB2 KRT7
14 linitis plastica 30.1 CDH1 KRT20 KRT7
15 squamous cell carcinoma 29.9 CDH1 EGFR ERBB2 KRT7 PTGS2 TP53
16 prostate cancer 29.9 CDH1 EGFR ENO2 EPHB2 ERBB2 KRT18
17 mucinous adenocarcinoma 29.8 EGFR KRT20 KRT7 TP53
18 small cell carcinoma of the bladder 29.8 ENO2 KRT20 KRT7
19 cystitis 29.8 KRT20 PTGS2 TP53 UPK1A UPK3A
20 ovarian brenner tumor 29.8 KRT18 KRT20 KRT7 UPK3A
21 spindle cell carcinoma 29.8 CDH1 ENO2 KRT7
22 ovarian cancer 1 29.7 CDH1 EGFR ERBB2 KRT7 TP53
23 adenocarcinoma 29.7 CDH1 EGFR ERBB2 MSH2 PTGS2 TP53
24 small cell carcinoma 29.6 EGFR ENO2 KRT20 KRT7 TP53
25 bladder cancer 29.6 BRINP1 CDH1 EGFR ERBB2 IFNA2 KRT18
26 adenoma 29.4 KRT7 MSH2 PTGS2 TP53
27 renal cell carcinoma, nonpapillary 29.2 CDH1 EGFR ENO2 IFNA2 KRT20 KRT7
28 endometrial cancer 28.5 CDH1 EGFR ERBB2 KRT20 KRT7 MSH2
29 lung cancer 28.2 CDH1 EGFR ENO2 ERBB2 KRT18 KRT20
30 sarcomatoid transitional cell carcinoma 12.5
31 prostate transitional cell carcinoma 12.2
32 ovary transitional cell carcinoma 12.2
33 ureter transitional cell carcinoma 12.2
34 fallopian tube transitional cell carcinoma 12.2
35 non-papillary transitional cell carcinoma of the bladder 12.1
36 bartholin's gland transitional cell carcinoma 12.1
37 endometrial transitional cell carcinoma 12.1
38 transitional cell carcinoma of the corpus uteri 12.1
39 urethra transitional cell carcinoma 12.1
40 kidney pelvis sarcomatoid transitional cell carcinoma 12.1
41 urinary tract non-invasive transitional cell neoplasm 12.1
42 infiltrating renal pelvis transitional cell carcinoma 12.0
43 infiltrating ureter transitional cell carcinoma 12.0
44 papillary transitional carcinoma 11.7
45 prostate cancer, hereditary, 1 11.0
46 prostate cancer, hereditary, 12 11.0
47 prostate cancer, hereditary, 13 11.0
48 prostate cancer, hereditary, 11 11.0
49 prostate cancer, hereditary, 2 11.0
50 fallopian tube carcinoma 11.0

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma

Symptoms & Phenotypes for Transitional Cell Carcinoma

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.93 BRINP1 PTGS2 CDH1 TP53 EGFR UBIAD1
2 digestive/alimentary MP:0005381 9.92 PTGS2 CDH1 TP53 EGFR EPHB2 ERBB2
3 embryo MP:0005380 9.86 PTGS2 CDH1 TP53 EGFR UBIAD1 ERBB2
4 neoplasm MP:0002006 9.5 PSCA PTGS2 CDH1 TP53 EGFR ERBB2
5 renal/urinary system MP:0005367 9.17 PTGS2 TP53 EGFR UPK2 UPK3A EPHB2

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 266)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 2, Phase 3, Phase 1 865-21-4 241903 13342
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 5280965 14956
5
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
6
Valrubicin Approved Phase 3,Phase 2,Phase 1 56124-62-0 41744
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
12
Aminolevulinic acid Approved Phase 3 106-60-5 137
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
14
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
16
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 5460373 44475014 11953898
17
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
18
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
19
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 6251 453
20
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
21
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
22
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
23
Ethanol Approved Phase 3 64-17-5 702
24
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
25
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
26
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
27
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
28 Tocopherol Approved, Investigational, Nutraceutical Phase 3
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
31
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
32
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
34
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
35
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
36
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 3,Phase 2 13422-55-4
37
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2 56-86-0 33032
38
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
39
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1
40
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
41
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
42
Fenretinide Investigational Phase 3 65646-68-6
43
Levulinic acid Experimental Phase 3 123-76-2 11579
44
Apaziquone Investigational Phase 3 114560-48-4 5813717
45
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
46
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
47 Antimitotic Agents Phase 2, Phase 3, Phase 1
48 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1
49 Anti-Infective Agents Phase 3,Phase 2,Phase 1
50 Antimetabolites Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 459)

# Name Status NCT ID Phase Drugs
1 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3 Cabazitaxel
2 Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Unknown status NCT01830231 Phase 2, Phase 3 Cabazitaxel;Vinflunine
3 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
4 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
5 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
6 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
7 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
8 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
9 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
10 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
11 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
12 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3 Vinflunine;Gemcitabine
13 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
14 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Completed NCT00315237 Phase 3 vinflunine and best supportive care
15 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3 Cisplatin
16 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
17 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
18 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
19 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
20 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
21 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
22 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
23 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
24 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
25 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
26 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
27 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
28 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
29 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
30 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
31 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
32 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
33 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Recruiting NCT03374488 Phase 3 Pembrolizumab;Epacadostat;Placebo
34 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
35 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Recruiting NCT02853305 Phase 3 Cisplatin;Carboplatin;Gemcitabine
36 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT02807636 Phase 3 Atezolizumab;Carboplatin;Gemcitabine;Cisplatin
37 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
38 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
39 Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Recruiting NCT03361865 Phase 3 Pembrolizumab;Epacadostat;Placebo
40 A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection Recruiting NCT02450331 Phase 3 Atezolizumab
41 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
42 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Recruiting NCT02793128 Phase 3 MitoGel™ instillations
43 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
44 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
45 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
46 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3 Nanoxel®M;Mitomycin-C
47 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Recruiting NCT02603432 Phase 3
48 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Active, not recruiting NCT02818725 Phase 3 Chemotherapy;panitumumab
49 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
50 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Genetic Tests for Transitional Cell Carcinoma

Anatomical Context for Transitional Cell Carcinoma

MalaCards organs/tissues related to Transitional Cell Carcinoma:

38
Kidney, Lymph Node, Prostate, Lung, Ovary, Testes, Endothelial

Publications for Transitional Cell Carcinoma

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 1226)
# Title Authors Year
1
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. ( 29416444 )
2018
2
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors? ( 29130135 )
2018
3
Iodine Content Analysis Using Dual-Energy Computed Tomography as a Biomarker of Transitional Cell Carcinoma, an Experience with Separation of the Clotted Blood and Tumorous Tissue. ( 29277821 )
2018
4
Prognostic factors and outcomes of primary transitional cell carcinoma of the ureter: a population-based study. ( 29029487 )
2017
5
Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. ( 28217972 )
2017
6
Microcystic transitional cell carcinoma: a rare tumor of the urinary bladder. ( 29154374 )
2017
7
Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy. ( 28506948 )
2017
8
Radical Cystectomy and Cutaneous Ureterostomy in 4 Dogs with Trigonal Transitional Cell Carcinoma: Description of Technique and Case Series. ( 27911468 )
2017
9
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). ( 28419193 )
2017
10
High-grade transitional cell carcinoma masquerading as a xanthogranulomatous pyelonephritis and perinephric abscess. ( 28491170 )
2017
11
Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma. ( 28778323 )
2017
12
In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells. ( 28133930 )
2017
13
Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. ( 26945449 )
2017
14
Urine cell-free microRNA as biomarkers for transitional cell carcinoma. ( 29187235 )
2017
15
Association Between Human Papillomavirus and Transitional Cell Carcinoma of the Bladder. ( 29101759 )
2017
16
Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. ( 27878359 )
2017
17
ODF4, MAGEA3, and MAGEB4: Potential Biomarkers in Patients with Transitional Cell Carcinoma ( 28865418 )
2017
18
The expression and clinical significance of ZBTB7 in transitional cell carcinoma of the bladder. ( 29085492 )
2017
19
VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. ( 28098864 )
2017
20
Expression of receptor tyrosine kinase targets PDGFR-I^, VEGFR2 and KIT in canine transitional cell carcinoma. ( 28884928 )
2017
21
Non-transitional cell carcinoma of the upper urinary tract: A case series among 305 cases at a tertiary urology institute. ( 28216943 )
2017
22
Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease. ( 28936147 )
2017
23
Thrombus-like Tumor of Renal Cell Carcinoma Mimicking Transitional Cell Carcinoma of Kidney: A Case Report. ( 27896135 )
2017
24
Transitional Cell Carcinoma of Urinary Bladder Manifesting as Extensive Retroperitoneal and Axillary Lymph Node Metastasis: An Extremely Rare Case Scenario Detected by<sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography Scan. ( 29142358 )
2017
25
Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma. ( 29124240 )
2017
26
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma. ( 28356972 )
2017
27
MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples. ( 29141625 )
2017
28
Cytological diagnosis of a rare case of cutaneous metastasis from transitional cell carcinoma, renal pelvis. ( 29233453 )
2017
29
Huge Prostatic Utricle with Transitional Cell Carcinoma in an Adult. ( 28065811 )
2017
30
Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. ( 28417194 )
2017
31
The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma. ( 28194179 )
2017
32
Transitional cell carcinoma of the renal pelvis with venous tumor thrombus. ( 28959157 )
2017
33
Transitional Cell Carcinoma of Lacrimal Sac. ( 28582372 )
2017
34
Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder. ( 29058301 )
2017
35
Transitional cell carcinoma involving graft kidney in a kidney transplant recipient: a case report. ( 28934936 )
2017
36
Association between chromosomal aberration of exfoliated bladder cells in the urine and oxidative stress in patients with bladder transitional cell carcinoma. ( 28693145 )
2017
37
Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target. ( 28871659 )
2017
38
Molecular cystoscopy: Micro-RNAs could be a marker for identifying genotypic changes for transitional cell carcinoma of the urinary bladder. ( 27127359 )
2016
39
Unusual Development of Pulmonary Tumor Embolism from Controlled Liver Metastases of Transitional Cell Carcinoma: An Autopsy Case. ( 27580549 )
2016
40
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. ( 27228294 )
2016
41
Novel somatic mutations identified by whole-exome sequencing in muscle-invasive transitional cell carcinoma of the bladder. ( 26893765 )
2016
42
Transitional Cell Carcinoma in the Pediatric Patient: A Review of the Literature. ( 26802795 )
2016
43
Transitional cell carcinoma: A rare development in congenital ureteropelvic junction obstruction kidney. ( 26941502 )
2016
44
WE-DE-BRA-03: Construction of An Ultrasound Guidance Platform for Image-Guided Radiotherapy with the Intent to Treat Transitional Cell Carcinoma. ( 28047007 )
2016
45
TOLERABILITY AND TUMOR RESPONSE OF A NOVEL LOW-DOSE PALLIATIVE RADIATION THERAPY PROTOCOL IN DOGS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER AND URETHRA. ( 26841125 )
2016
46
A pure primary transitional cell carcinoma of the ovary: A rare case report with literature review. ( 27127747 )
2016
47
Primary Retroperitoneal Transitional Cell Carcinoma - A Rare Clinical Entity. ( 27734432 )
2016
48
Choroidal Metastasis as an Unusual Initial Presentation of Transitional Cell Carcinoma of the Kidney. ( 27920701 )
2016
49
Transitional cell carcinoma with extension of the renal vein and IVC tumor thrombus: report of three cases and literature review. ( 28031042 )
2016
50
Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors. ( 27366313 )
2016

Variations for Transitional Cell Carcinoma

Copy number variations for Transitional Cell Carcinoma from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 26136 1 197500000 205300000 Amplification LRRN2 Urothelial cell carcinoma
2 26141 1 197500000 205300000 Amplification MDM4 Urothelial cell carcinoma
3 26154 1 197500000 205300000 Loss Urothelial cell carcinoma
4 42679 10 3800000 6700000 Amplification PFKFB3 Urothelial cell carcinoma
5 49670 11 110000000 115400000 Loss ANKK1 Urothelial cell carcinoma
6 49671 11 110000000 115400000 Loss DRD2 Urothelial cell carcinoma
7 49672 11 110000000 115400000 Loss NCAM1 Urothelial cell carcinoma
8 49673 11 110000000 115400000 Loss TTC12 Urothelial cell carcinoma
9 52333 11 16100000 21600000 Loss PLEKHA7 Urothelial cell carcinoma
10 58688 11 69200000 70700000 Amplification CCND1 Urothelial cell carcinoma
11 58689 11 69200000 70700000 Amplification FGF19 Urothelial cell carcinoma
12 58690 11 69200000 70700000 Amplification FGF3 Urothelial cell carcinoma
13 58692 11 69200000 70700000 Amplification FGF4 Urothelial cell carcinoma
14 58694 11 69200000 70700000 Amplification ORAOV1 Urothelial cell carcinoma
15 58695 11 69200000 70700000 Amplification TPCN2 Urothelial cell carcinoma
16 58889 11 70700000 74900000 Amplification Urothelial cell carcinoma
17 58890 11 70700000 74900000 Amplification C11orf76 Urothelial cell carcinoma
18 58891 11 70700000 74900000 Amplification SHANK2 Urothelial cell carcinoma
19 64483 12 128700000 132349534 Loss FZD10 Urothelial cell carcinoma
20 69470 12 55200000 56300000 Amplification ARHGAP9 Urothelial cell carcinoma
21 69471 12 55200000 56300000 Amplification DCTN2 Urothelial cell carcinoma
22 69472 12 55200000 56300000 Amplification GLI1 Urothelial cell carcinoma
23 69473 12 55200000 56300000 Amplification INHBC Urothelial cell carcinoma
24 69474 12 55200000 56300000 Amplification KIF5A Urothelial cell carcinoma
25 69475 12 55200000 61400000 Amplification CDK4 Urothelial cell carcinoma
26 69476 12 55200000 61400000 Amplification METTL1 Urothelial cell carcinoma
27 69477 12 55200000 61400000 Amplification TSFM Urothelial cell carcinoma
28 69795 12 56300000 61400000 Amplification FAM19A2 Urothelial cell carcinoma
29 69796 12 56300000 61400000 Amplification SLC16A7 Urothelial cell carcinoma
30 70900 12 66000000 69800000 Amplification CNOT2 Urothelial cell carcinoma
31 70901 12 66000000 69800000 Amplification CPM Urothelial cell carcinoma
32 70902 12 66000000 69800000 Amplification IFNG Urothelial cell carcinoma
33 70903 12 66000000 69800000 Amplification IL22 Urothelial cell carcinoma
34 70904 12 66000000 69800000 Amplification IL26 Urothelial cell carcinoma
35 70910 12 66000000 69800000 Amplification MDM2 Urothelial cell carcinoma
36 70911 12 66000000 69800000 Amplification TM4SF3 Urothelial cell carcinoma
37 71411 12 69800000 74100000 Amplification LGR5 Urothelial cell carcinoma
38 71412 12 69800000 74100000 Amplification THAP2 Urothelial cell carcinoma
39 71413 12 69800000 74100000 Amplification TMEM19 Urothelial cell carcinoma
40 71414 12 69800000 74100000 Amplification TPH2 Urothelial cell carcinoma
41 71668 12 74100000 78700000 Amplification NAV3 Urothelial cell carcinoma
42 72907 12 87500000 91200000 Amplification KITLG Urothelial cell carcinoma
43 73109 12 91200000 94800000 Amplification PLXNC1 Urothelial cell carcinoma
44 79797 13 77800000 86500000 Loss Urothelial cell carcinoma
45 94764 15 70400000 73100000 Loss SDFR1 Urothelial cell carcinoma
46 109762 17 28800000 35600000 Amplification ERBB2 Urothelial cell carcinoma
47 109763 17 28800000 35600000 Amplification TCAP Urothelial cell carcinoma
48 123109 18 66900000 71300000 Loss Urothelial cell carcinoma
49 123110 18 66900000 71300000 Loss SDCCAG33 Urothelial cell carcinoma
50 123111 18 66900000 71300000 Loss ZADH2 Urothelial cell carcinoma

Expression for Transitional Cell Carcinoma

Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for Transitional Cell Carcinoma

GO Terms for Transitional Cell Carcinoma

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 CDH1 ENO2 KRT18 KRT7 KRT8 PSCA
2 intermediate filament GO:0005882 9.26 KRT18 KRT20 KRT7 KRT8
3 apical plasma membrane GO:0016324 9.1 EGFR ERBB2 UPK1A UPK1B UPK2 UPK3A

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 wound healing GO:0042060 9.65 EGFR ERBB2 TP53
2 keratinization GO:0031424 9.56 KRT18 KRT20 KRT7 KRT8
3 cell surface receptor signaling pathway GO:0007166 9.55 EGFR ERBB2 IFNA2 UPK1A UPK1B
4 cell morphogenesis GO:0000902 9.5 EGFR EPHB2 UPK3A
5 negative regulation of ERBB signaling pathway GO:1901185 9.49 EGFR ERBB2
6 determination of adult lifespan GO:0008340 9.46 MSH2 TP53
7 response to UV-B GO:0010224 9.43 MSH2 TP53
8 hepatocyte apoptotic process GO:0097284 9.4 KRT18 KRT8
9 positive regulation of synaptic plasticity GO:0031915 9.37 EPHB2 PTGS2
10 cornification GO:0070268 9.26 KRT18 KRT20 KRT7 KRT8
11 epithelial cell differentiation GO:0030855 8.92 UPK1A UPK1B UPK2 UPK3A

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.62 KRT18 KRT7 KRT8 UPK1B
2 protein binding GO:0005515 9.58 BRINP1 CDH1 EGFR ENO2 EPHB2 ERBB2
3 protein phosphatase binding GO:0019903 9.43 EGFR ERBB2 TP53
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 EGFR ERBB2
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHB2 ERBB2

Sources for Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....